Search research articles
Contact Us
Filters
Showing results (1-10 of 49) with videos related to
Page
of 5
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies
Marc A Koopmanschap
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 9, 2003
The drug budget silo mentality: the Dutch case
Marc A Koopmanschap, Frans F H Rutten
Pharmacoeconomics
|
March 8, 2005
The friction-cost method : replacement for nothing and leisure for free?
Werner B F Brouwer, Marc A Koopmanschap
International Journal of Technology Assessment in Health Care
|
July 17, 2003
Cost-effectiveness analysis: can we reduce variability in costing methods?
Taghreed Adam, Marc A Koopmanschap, David B Evans
International Journal of Technology Assessment in Health Care
|
April 16, 2010
Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals
Marc A Koopmanschap, Elly A Stolk, Xander Koolman
Expert Review of Pharmacoeconomics & Outcomes Research
|
July 21, 2012
Value for money of drug regulation
Jacoline C Bouvy, Marc A Koopmanschap, Huub Schellekens
Drug Safety
|
March 31, 2015
Epidemiology of adverse drug reactions in Europe: a review of recent observational studies
Jacoline C Bouvy, Marie L De Bruin, Marc A Koopmanschap
Pharmacoeconomics
|
July 3, 2002
Standardisation of costs: the Dutch Manual for Costing in economic evaluations
Jan B Oostenbrink, Marc A Koopmanschap, Frans F H Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 29, 2004
Economic valuation of informal care. An overview of methods and applications
Bernard van den Berg, Werner B F Brouwer, Marc A Koopmanschap
Health Policy (Amsterdam, Netherlands)
|
May 1, 2013
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time
Frank G Sandmann, Margreet G Franken, Adri Steenhoek, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 49) with videos related to
Sort By:
Page
of 5
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies
Marc A Koopmanschap
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 9, 2003
The drug budget silo mentality: the Dutch case
Marc A Koopmanschap, Frans F H Rutten
Pharmacoeconomics
|
March 8, 2005
The friction-cost method : replacement for nothing and leisure for free?
Werner B F Brouwer, Marc A Koopmanschap
International Journal of Technology Assessment in Health Care
|
July 17, 2003
Cost-effectiveness analysis: can we reduce variability in costing methods?
Taghreed Adam, Marc A Koopmanschap, David B Evans
International Journal of Technology Assessment in Health Care
|
April 16, 2010
Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals
Marc A Koopmanschap, Elly A Stolk, Xander Koolman
Expert Review of Pharmacoeconomics & Outcomes Research
|
July 21, 2012
Value for money of drug regulation
Jacoline C Bouvy, Marc A Koopmanschap, Huub Schellekens
Drug Safety
|
March 31, 2015
Epidemiology of adverse drug reactions in Europe: a review of recent observational studies
Jacoline C Bouvy, Marie L De Bruin, Marc A Koopmanschap
Pharmacoeconomics
|
July 3, 2002
Standardisation of costs: the Dutch Manual for Costing in economic evaluations
Jan B Oostenbrink, Marc A Koopmanschap, Frans F H Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 29, 2004
Economic valuation of informal care. An overview of methods and applications
Bernard van den Berg, Werner B F Brouwer, Marc A Koopmanschap
Health Policy (Amsterdam, Netherlands)
|
May 1, 2013
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time
Frank G Sandmann, Margreet G Franken, Adri Steenhoek, et al.
Page
of 5